A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
A Phase Ib/IIa, multicentre, open label, dose-escalation study to evaluate the safety,
tolerability, and preliminary effectiveness of intratumoural tigilanol tiglate in combination
with intravenous pembrolizumab in adult patients with unresectable, Stage IIIB to IV M1c
melanoma.